104
Participants
Start Date
June 22, 2022
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2027
Deramiocel (CAP-1002)
Cohort A: CAP-1002A manufactured in Los Angeles, CA; Cohort B: CAP-1002B manufactured in San Diego, CA
Placebo
Placebo
University of Virginia Children's Hospital, Charlottesville
Rare Disease Research NC LLC, Hillsborough
Rare Disease Research, LLC, Atlanta
Akron Children's Hospital, Akron
Cincinnati Children's Hospital Medical Center, Cincinnati
University of Iowa Hospitals and Clinics, Iowa City
Children's Wisconsin, Milwaukee
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Saint Louis Children's Hospital, St Louis
University of Missouri Health Care, Columbia
Arkansas Children's Hospital, Little Rock
Children's Health Specialty Care Pavilion, Dallas
Children's Hospital Colorado, Aurora
University of Utah Hospital, Salt Lake City
Phoenix Children's Hospital, Phoenix
Children's Hospital of Los Angeles, Division of Neurology, Los Angeles
UCSD Altman Clinical and Translational Research Institute, La Jolla
University of California, Davis, Sacramento
Seattle Children's, Seattle
Boston Children's Hospital, Boston
Capricor Inc.
INDUSTRY